We are seeking a Prnicpal SAP S/4HANA Solution Architect to provide end-to-end architecture leadership and long-term ownership of the S/4HANA solution landscape. While the programme is approaching go-live in July, the primary focus of this role is to define and govern the target architecture, ensure architectural integrity across all workstreams, and shape the roadmap for ongoing evolution, optimisation, and innovation.
The Solution Architect will provide governance and design assurance across the SAP landscape (process, data, integration, security, and operations), supporting delivery through go-live and establishing a sustainable foundation for steady-state operations. This includes adherence to SAP Clean Core principles and enterprise standards, clear design decision-making, and a forward-looking architecture roadmap, with SAP BTP and SAP Integration Suite/CPI as key enabling components for integration and extensibility.
Bachelor’s degree in computer science, information management, mathematics, statistics, biostatistics, business, or related field; advanced degree preferred
8-12 years of technology experience, preferably in Life Sciences or within a regulated environment
Desired Skills
SAP certifications in S/4HANA, BTP, or Integration.
Soft Skills
Excellent communication and stakeholder management skills.
Strong analytical and problem-solving abilities.
Proven leadership in complex, multi-stream delivery environments.
Delivery-focused with strong attention to detail
The annual base salary for this position ranges from $175,000 to $197,000. In addition, this position is eligible for an annual performance pay bonus. Exact compensation may vary based on skills, training, knowledge, and experience. Alkermes offers a competitive benefits package. Additional details can be found on our careers website: www.alkermes.com/careers#working-here
#LI-AH1
Why join Team Alkermes?
Alkermes applies its decades of deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, and a pipeline of clinical and preclinical candidates in development for various psychiatric and neurological disorders.
We are proud to have been recognized as an employer of choice by many national organizations. In 2024 and 2025, we were certified as a Great Place to Work in the U.S. and named one of Massachusetts’ Top Places to Work by the Boston Globe, a Best Place to Work in Greater Cincinnati by the Cincinnati Business Courier and recognized as a Best Place to Work in BioPharma by Fortune Magazine.
Alkermes, Inc. is an equal employment opportunity employer and does not discriminate against any qualified applicant or employee because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender expression and identity, disability, genetic information, veteran status, military status, application for military service or any other characteristic protected by local, state or federal law. Alkermes also complies with all work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Alkermes is an E-Verify employer.

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.
Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.
Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment.
Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
See our Community Guidelines: https://www.alkermes.com/social-community-guidelines